{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:49:41Z","timestamp":1782247781748,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019110","name":"Institute of Basic Medical Sciences","doi-asserted-by":"publisher","award":["QMSI2019-05"],"award-info":[{"award-number":["QMSI2019-05"]}],"id":[{"id":"10.13039\/501100019110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27629","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T12:57:28Z","timestamp":1710161848000},"page":"e27629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mechanisms of vemurafenib-induced anti-tumor effects in ATC FRO cells"],"prefix":"10.1016","volume":"10","author":[{"given":"Jingwei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1013-9988","authenticated-orcid":false,"given":"Li","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e27629_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0000000000000918","article-title":"Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy","volume":"35","author":"Jungels","year":"2023","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27629_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/CCO.0000000000000797","article-title":"BRAF mutations in thyroid cancer","volume":"34","author":"Scheffel","year":"2022","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27629_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44464-1","article-title":"BRAFV600E genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspiration","volume":"13","author":"Lu","year":"2023","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e27629_bib4","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.7150\/thno.57689","article-title":"Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS","volume":"11","author":"Oh","year":"2021","journal-title":"Theranostics"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e27629_bib5","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1111\/jcmm.17443","article-title":"BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers","volume":"26","author":"Gao","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e27629_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.689992","article-title":"Role of lncRNA BANCR in human cancers: an updated review","volume":"9","author":"Hussen","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27629_bib8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1101\/gr.140061.112","article-title":"BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration","volume":"22","author":"Flockhart","year":"2012","journal-title":"Genome Res."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27629_bib7","first-page":"1354","article-title":"Emerging roles of lncRNA in cancer and therapeutic opportunities","volume":"9","author":"Jiang","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27629_bib9","first-page":"5865","article-title":"lncRNA BANCR promotes EMT in PTC via the Raf\/MEK\/ERK signaling pathway","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27629_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12957-020-01923-7","article-title":"BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features","volume":"18","author":"Shi","year":"2020","journal-title":"World J. Surg. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27629_bib11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27629_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13044-023-00147-7","article-title":"Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer","volume":"16","author":"Lang","year":"2023","journal-title":"Thyroid Res."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27629_bib13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2024.e27629_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.906197","article-title":"Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K\/AKT signaling pathway to suppress breast cancer","volume":"12","author":"Dai","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27629_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3892\/ol.2021.12845","article-title":"Effect of BRAF-mediated PI3K\/AKT\/mTOR pathway on biological characteristics and chemosensitivity of NSCLC A549\/DDP cells","volume":"22","author":"Ren","year":"2021","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27629_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27629_bib17","first-page":"3021","article-title":"Potential synergistic effects of sorafenib and CP-31398 for treating anaplastic thyroid cancer with p53 mutations","volume":"19","author":"Wu","year":"2020","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27629_bib18","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27629_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-91442-8_6","volume":"211","author":"Garbe","year":"2018","journal-title":"Vemurafenib. Recent Results Cancer Res."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27629_bib20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27629_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ymthe.2020.09.024","article-title":"A nuclear long non-coding RNA LINC00618 accelerates ferroptosis in a manner dependent upon apoptosis","volume":"29","author":"Wang","year":"2021","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27629_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1568011043352867","article-title":"Amplification of anticancer drug-induced DNA damage and apoptosis by DNA-binding compounds","volume":"4","author":"Kawanishi","year":"2004","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27629_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4252\/wjsc.v12.i1.87","article-title":"HIF-2\u03b1 regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K\/AKT\/mTOR signaling","volume":"12","author":"Bai","year":"2020","journal-title":"World J. Stem Cell."},{"key":"10.1016\/j.heliyon.2024.e27629_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110960","article-title":"Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K\/AKT and MAPK\/EKR1\/2 signaling pathways","volume":"136","author":"Shi","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e27629_bib25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.biopha.2018.04.072","article-title":"Inhibition of PI3K\/AKT\/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells","volume":"103","author":"Yang","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27629_bib26","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3390\/ijms19113634","article-title":"Scutellariae radix and coptidis rhizoma improve glucose and lipid metabolism in T2DM rats via regulation of the metabolic profiling and MAPK\/PI3K\/AKT signaling pathway","volume":"19","author":"Cui","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27629_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14715\/cmb\/2021.67.2.2","article-title":"Naringenin inhibits human breast cancer cells (MDA-MB-231) by inducing programmed cell death, caspase stimulation, G2\/M phase cell cycle arrest and suppresses cancer metastasis","volume":"67","author":"Qi","year":"2021","journal-title":"Cell. Mol. Biol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27629_bib28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1039\/c8pp00109j","article-title":"Photobiomodulation prevents DNA fragmentation of alveolar epithelial cells and alters the mRNA levels of caspase 3 and Bcl-2 genes in acute lung injury","volume":"17","author":"Sergio","year":"2018","journal-title":"Photochem. Photobiol. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27629_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.14715\/cmb\/2021.67.2.25","article-title":"Expression of FOXA1 gene regulates the proliferation and invasion of human gastric cancer cells","volume":"67","author":"Dai","year":"2021","journal-title":"Cell. Mol. Biol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27629_bib30","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.4251\/wjgo.v13.i9.1164","article-title":"Scoparone inhibits pancreatic cancer through PI3K\/AKT signaling pathway","volume":"13","author":"Li","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27629_bib31","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/IJPM.IJPM_462_19","article-title":"Xanthoceraside induces cell apoptosis through downregulation of the PI3K\/AKT\/Bcl-2\/Bax signaling pathway in cell lines of human bladder cancer","volume":"64","author":"Chai","year":"2021","journal-title":"Indian J. Pathol. Microbiol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27629_bib32","first-page":"567","article-title":"DPC4 regulates the proliferation, invasion and epithelial-mesenchymal transition of pancreatic cancer cells by inhibiting PI3K\/AKT\/mTOR signaling pathway","volume":"26","author":"Deng","year":"2020","journal-title":"Advances in Anatomy"},{"key":"10.1016\/j.heliyon.2024.e27629_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12449","article-title":"The BRAF activated non-coding RNA: a pivotal long non-coding RNA in human malignancies","volume":"51","author":"Liu","year":"2018","journal-title":"Cell Prolif."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27629_bib34","first-page":"859","article-title":"Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF\/MEK\/ERK signaling pathway","volume":"40","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27629_bib35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/jop.12968","article-title":"Long non-coding RNA BANCR promotes proliferation and migration in oral squamous cell carcinoma via MAPK signaling pathway","volume":"50","author":"Yao","year":"2021","journal-title":"J. Oral Pathol. Med."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024036600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024036600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:25:24Z","timestamp":1782246324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024036600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024036600"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27629","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of vemurafenib-induced anti-tumor effects in ATC FRO cells","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27629"}}